MEDICINES Sans Frontieres (MSF) has joined with a range of other organisations in filing a patent challenge with the European Patent Office in relation to the hepatitis C sofosbuvir.
The groups aim to challenge Gilead's monopoly on the expensive therapy, in a bid to "remove barriers that prevent millions of people receiving treatment".
MSF said the price of sofosbuvir is keeping it out of reach for many people who need it, with treatment being rationed or unavailable right across the globe.
"A drug that cures doesn't do any good if the people who need it can't afford it," MSF said.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 17